Biotech RadarJobs updated

COMPANY

Precigen

HQ: Germantown, MD source · precigen.com ↗ · Mid-Atlantic

FDA-approved therapeutic company Clinical Phase 3

11 open jobs · last seen Oct 23, 2026 · 8 sources

Keywords: oncology immunology infectious disease immuno-oncology infectious diseases Recurrent Respiratory Papillomatosis Papillomavirus Infection Papillomaviridae Cervical Cancer HPV-Related Carcinoma HPV-Related Malignancy Recurrent Cervical Carcinoma Metastatic Cervical Cancer Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Ovarian Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Refractory Fallopian Tube Carcinoma Refractory Ovarian Carcinoma Refractory Primary Peritoneal Carcinoma Stage III Fallopian Tube Cancer AJCC V8 Stage III Ovarian Cancer AJCC V8 Stage III Primary Peritoneal Cancer AJCC V8 Stage IIIA Fallopian Tube Cancer AJCC V8 Stage IIIA Ovarian Cancer AJCC V8 Stage IIIA Primary Peritoneal Cancer AJCC V8 Stage IIIA1 Fallopian Tube Cancer AJCC V8 Stage IIIA1 Ovarian Cancer AJCC V8 Stage IIIA2 Fallopian Tube Cancer AJCC V8 Stage IIIA2 Ovarian Cancer AJCC V8 Stage IIIB Fallopian Tube Cancer AJCC V8 Stage IIIB Ovarian Cancer AJCC V8 Stage IIIB Primary Peritoneal Cancer AJCC V8 Stage IIIC Fallopian Tube Cancer AJCC V8 Stage IIIC Ovarian Cancer AJCC V8 Stage IIIC Primary Peritoneal Cancer AJCC V8 Stage IV Fallopian Tube Cancer AJCC V8 Stage IV Ovarian Cancer AJCC V8 Stage IV Primary Peritoneal Cancer AJCC V8 Stage IVA Fallopian Tube Cancer AJCC V8 Stage IVA Ovarian Cancer AJCC V8 Stage IVA Primary Peritoneal Cancer AJCC V8 Stage IVB Fallopian Tube Cancer AJCC V8

Location: Germantown, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

11Open jobs$79.0MRaised (2 yrs)5Trials (company is sponsor)1FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Process Engineer - Drug Substance ManufacturingGermantown, MD, USOct 20, 2026Oct 11, 2026
Technician, MetrologyGermantown, MD, USOct 7, 2026Oct 11, 2026
Lead Validation EngineerGermantown, MD, USSep 29, 2026Oct 11, 2026
Materials Management Associate IIGermantown, MD, USSep 26, 2026Oct 11, 2026
Director, Gene Therapy Manufacturing, Drug SuGermantown, MD, USSep 22, 2026Oct 11, 2026

See all 11 jobs

Timeline

  1. Trial start Phase 2: PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer source ↗
  2. Debt Debt financing: $125M (up to, as announced), announced Sep 3, 2025. Source: SEC filing. source ↗
  3. FDA FDA New drug/biologic (novel): PAPZIMEOS (zopapogene imadenovec-drba) — BLA125832, Aug 14, 2025. Applicant at approval: Precigen, Inc. source ↗
  4. Raise Private placement: $79M (total, as published), announced Dec 27, 2024. Source: SEC filing. source ↗
  5. Trial start Phase 4: Zopa Retreatment and Vector Shedding in Adults With RRP source ↗
  6. Trial start Phase 1/Phase 2: Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis source ↗
  7. Trial start Phase 1: PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS source ↗
  8. Trial start Phase 1: Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $79.0M · Debt: $125.0M. Last 2 years.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT06157151PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerPhase 2RecruitingNov 11, 2025Nov 11, 2026 (estimated)
NCT06538480Zopa Retreatment and Vector Shedding in Adults With RRPPhase 4RecruitingJul 11, 2024Dec 2, 2027 (estimated)
NCT04724980Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory PapillomatosisPhase 1/Phase 2Active, not recruitingMar 16, 2021Jun 5, 2024 (actual)
NCT03907527Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerPhase 1Active, not recruitingApr 30, 2019Dec 15, 2024 (estimated)
NCT03927261PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDSPhase 1Active, not recruitingMay 20, 2019Aug 1, 2024 (actual)

FDA records (last 2 years)

Open jobs 11

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Process Engineer - Drug Substance ManufacturingGermantown, MD, USOct 20, 2026Oct 11, 2026Mid
Technician, MetrologyGermantown, MD, USOct 7, 2026Oct 11, 2026Entry
Lead Validation EngineerGermantown, MD, USSep 29, 2026Oct 11, 2026Senior
Materials Management Associate IIGermantown, MD, USSep 26, 2026Oct 11, 2026Mid
Director, Gene Therapy Manufacturing, Drug SuGermantown, MD, USSep 22, 2026Oct 11, 2026Senior
Site MicrobiologistGermantown, MD, USSep 18, 2026Oct 11, 2026Mid
Sr Manager, Global Promotional Regulatory AffairsGermantown, MD, USSep 10, 2026Oct 11, 2026Senior
GMP Manufacturing AssociateGermantown, MD, USSep 4, 2026Oct 11, 2026Entry
Procurement ManagerGermantown, MD, USAug 4, 2026Oct 11, 2026Mid
GMP Cleaning AssociateGermantown, MD, USJul 31, 2026Oct 11, 2026Entry
Senior Manager/Manager, Regulatory AffairsGermantown, MD, USJun 1, 2026Oct 11, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Precigen on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback